Simecos
Novel Arthritis Treatment with focus on natural Chitin Oligosaccharides
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Simecos project word cloud
Explore the words cloud of the Simecos project. It provides you a very rough idea of what is the project "Simecos" about.
Project "Simecos" data sheet
The following table provides information about the project.
| Coordinator |
GENIS HF
Organization address contact info |
| Coordinator Country | Iceland [IS] |
| Project website | http://www.genis.is/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-03-01 to 2017-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GENIS HF | IS (SIGLUFJORDUR) | coordinator | 50˙000.00 |
Map
Project objective
Osteoarthritis (OA) is one of the leading causes of global disability, especially among the Elderly populations – approximately 10–12% of the adult population in the world has symptomatic OA. Specifically, it affects more than 40 million people in Europe. Currently there is no cure for OA – there are no current therapies available that can reverse or halt the progression of osteoarthritis. OA's control strategy mainly consists of palliative pain treatment as there are several medicines on the market can alleviate pain and improve function in OA patients (e.g. analgesics, NSAIDs, opioids). Genis offers a revolutionary approach for the resolution of inflammation and tissue regeneration for OA patients - SIMECOS. SIMECOS is a biocompatible and bioactive drug, derived from Genis' patented food supplement BenectaTM , which provides less risk of side effects, reduced patient recovery time, protection of articular tissues, reduced scar tissue formation and increased success rate for treating OA disease.Genis' approach has been validated in a relevant environment (in vivo and in vitro studies) supported by Pre-Clinical and Phase I Clinical trials for BenectaTM, showing safety of the compound and its pronounced effect of resolution of inflammation and tissue regeneration.
Genis is a small innovative biotechnology company from Siglufjörður, Iceland, whose aim is to discover, develop and commercialize novel and life changing pharmaceutical products, supplements and medical devices derived from crustacean exoskeletons. With their novel biocompatible and bioactive drug SIMECOS they seek to disrupt the pharmaceutical market for OA's treatment, and to access a more than €45 billion market in Europe.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIMECOS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SIMECOS" are provided by the European Opendata Portal: CORDIS opendata.